Continuing Medical Education

Thalassaemia (part 2): Management

N A Alli, M Patel, J Poole, Y Goga, F Fazel, N Novitzky, S Parasnath, F Bassa

Abstract


-

Authors' affiliations

N A Alli, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa

M Patel, Department of Medicine, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

J Poole, Department of Paediatrics and Child Health, Paediatric Haematology/Oncology Unit, Faculty of Health Sciences, University of the Witwatersrand and Charlotte Maxeke Hospital, Johannesburg, South Africa

Y Goga, Department of Paediatrics and Child Health, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Inkosi Albert Luthuli Central Hospital, Durban, South Africa

F Fazel, Blood Centre, Rondebosch Medical Centre, Cape Town, South Africa

N Novitzky, Division of Clinical Haematology, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa

S Parasnath, Department of Clinical Haematology, Inkosi Albert Luthuli Central Hospital and Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

F Bassa, Division of Clinical Haematology, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa

Full Text

PDF (253KB)

Keywords

Thalassaemia major; Thalassaemia intermedia; Chronic blood transfusion; Iron chelation; Novel therapies

Cite this article

South African Medical Journal 2021;111(9):825-833.

Article History

Date submitted: 2021-09-02
Date published: 2021-09-02

Article Views

Abstract views: 1098
Full text views: 617

Comments on this article

*Read our policy for posting comments here